| Uday R Popat, M.D. |
Present Title & Affiliation
Primary Appointment
Bio Statement
Dr. Uday Popat graduated from the
Research Interests
Myelofibrosis: Reduced intensity allogeneic transplantation(SCT) for myelofibrosis: This is a novel study, first protocol in this disease at MDACC and the largest single center study, which is still accruing patients. Our preliminary results are encouraging. If these hold over a period of time, this should become standard of care and establish allogeneic transplant as a viable, curative therapy. In a separate study we showed that long term remission was possible in patients with AML post MF after SCT. This finding has not been previously reported.
Multiple Sclerosis: My previous study and current ongoing study at MDACC will go some way in establishing a role for autologous transplantation in this disease. Our study on allogeneic transplantation for patients with ALS was novel and although negative for clinical endpoints did show significant trafficking of donor hematopoietic stem cells to diseased areas in central nervous system.
Imapct of comorbidities on SCT: To identify patients most suitable for allo transplant and to identify the most suitable transplant strategy for patients with comorbidities.
Risk factors predicting stem cell mobilization failure.Office Address
1515 Holcombe
Unit Number: 423
Houston, TX 77030
Room Number: FC5.3026
Education & Training
Degree-Granting Education | |
| 2003 | Royal College of Pathologists, London, United Kingdom, FRCPath, Hematology |
| 1995 | Royal College of Pathologists, London, United Kingdom, MRCPath, Hematology |
| 1994 | Royal College of Pathologists, London, United Kingdom, Dip RCPath, Hematology |
| 1991 | Royal College of Physicians, London, United Kingdom, MRCP, Internal Medicine |
| 1988 | University of Bombay, Lokmanya Tilak Municipal Medical College & Hospital, Bomabay, India, MD, Internal Medicine |
| 1983 | University of Bombay, Lokmanya Tilak Municipal Medical College & Hospital, Bombay, India, MB, BS, Med School |
Postgraduate Training | |
| 1997-1999 | Residency, Internal Medicine, Baylor College of Medicine, Houston, TX |
| 1996-1997 | Fellowship, Hematology and Medical Oncology, Baylor College of Medicine, Houston, TX |
| 1995-1996 | Fellowship, Bone Marrow Transplant, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 1994-1995 | Fellowship, Bone Marrow Transplant, Royal Free Hospital and School of Medicine University of London, London, United Kingdom |
| 1983-1988 | Internship and Residency, Internal Medicine, Lokmanya Tilak Municipal Medical College and General Hospital, University of Bombay, Bombay, India |
Board Certifications
| 12/2022 | American Board of Internal Medicine, Internal Medicine |
| 12/2022 | American Board of Internal Medicine, Medical Oncology |
| 12/2022 | American Board of Internal Medicine, Hematology |
Experience/Service
Academic Appointments
Administrative Appointments/Responsibilities
Institutional Committee Activities
Honors and Awards
| 2009-2011 | Best Doctors in America, Best Doctors, Inc. |
Selected Publications
Peer-Reviewed Original Research Articles | ||
| 1. | Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. Biol Blood Marrow Transplant 19(3):410-7, 3/2013. e-Pub 11/2/2012. PMID: 23128322. | |
| 2. | Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biol Blood Marrow Transplant 19(2):214-20, 2/2013. e-Pub 9/13/2012. PMID: 22982533. | |
| 3. | Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. e-Pub 1/2013. PMID: 23330820. | |
| 4. | de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 12/2012. PMID: 23234514. | |
| 5. | Akpek G, Pasquini MC, Logan B, Agovi MA, Lazarus HM, Marks DI, Bornhaeüser M, Ringdén O, Maziarz RT, Gupta V, Popat U, Maharaj D, Bolwell BJ, Rizzo JD, Ballen KK, Cooke KR, McCarthy PL, Ho VT. Effects of spleen status on early outcomes after hematopoietic cell transplantation. Bone Marrow Transplant. e-Pub 12/2012. PMID: 23222382. | |
| 6. | Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant 47(2):212-6, 2/2012. e-Pub 3/21/2011. PMID: 21423123. | |
| 7. | Hou P, Popat UR, Lindsay RJ, Jackson EF, Choi H. A practical approach for a wide range of liver iron quantitation using a magnetic resonance imaging technique. Radiol Res Pract 2012:207391, 2012. e-Pub 12/2012. PMCID: PMC3530181. | |
| 8. | Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C, Stolar K, Qazilbash M, Hosing C, Kebriaei P, Couriel DR, Champlin RE, Saliba R, Popat U. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol 86(11):954-6, 11/2011. e-Pub 9/21/2011. PMID: 21948087. | |
| 9. | Ciurea SO, de Lima M, Giralt S, Saliba R, Bueso-Ramos C, Andersson BS, Hosing CM, Verstovsek S, Champlin RE, Popat U. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant 16(4):555-9, 4/2010. e-Pub 1/29/2010. PMID: 20005966. | |
| 10. | Parmar S, Del Lima M, Zou Y, Patah PA, Liu P, Cano P, Rondon G, Pesoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina M. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 114(14):2884-7, 10/1/2009. e-Pub 8/4/2009. PMCID: PMC19654407. | |
| 11. | Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma. Biol Blood Marrow Transplant 15(6):718-23, 6/2009. e-Pub 4/2009. PMCID: PMC19450756. | |
| 12. | Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U. Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 84(6):335-7, 6/2009. e-Pub 3/2009. PMCID: PMC19384931. | |
| 13. | Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortés JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma 9 Suppl 3:S261-5, 2009. PMCID: PMC19778850. | |
| 14. | Appel SH, Engelhardt JI, Henkel JS, Siklos L, Beers DR, Yen AA, Simpson EP, Luo Y, Carrum G, Heslop HE, Brenner MK, Popat U. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology 71(17):1326-34, 10/2008. PMCID: PMC18936424. | |
| 15. | Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA, Champlin RE, Ciurea SE, Manshouri T, Pierce SM, Kantarjian HM, Verstovsek S. The natural history and treatment outcome of blast phase BCR-ABL negative myeloproliferative neoplasms. Blood 112(5):1628-37, 9/1/2008. e-Pub 6/19/2008. PMCID: PMC18566326. | |
| 16. | Nash RA, Stuve O, Bowen JD, Frohman EM, Griffith LM, Hutton GJ, Kraft GH, Popat U, Racke MK, Muraro PA. Autologous HSCT for advanced MS: is the glass half-empty or really half-full? Brain 131(Pt 2)(Pt 2):e89, 2/2008. e-Pub 9/2007. PMCID: PMC17908695. | |
| 17. | Samuelson SJ, Popat U, Prchal JT. Marrow fibrosis does not account for circulating CD34+ cells in myelofibrosis with myeloid metaplasia. Haematologica 92(3 Suppl)(4):ELT02, 4/2007. PMID: 17405759. | |
| 18. | Popat U, Frost A, Liu E, Guan Y, Durette A, Reddy V, Prchal JT. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Blood 107(9)(9):3486-3488, 5/1/2006. e-Pub 1/17/2006. PMID: 16418333. | |
| 19. | Popat U, Heslop HE, Durett A, May R, Krance RA, Brenner MK, Carrum G. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant 37(6)(6):547-52, 3/2006. PMID: 16462757. | |
| 20. | Rousseau RF, Biagi E, Dutour A, Yvon ES, Brown MP, Lin T, Mei Z, Grilley B, Popek E, Heslop HE, Gee AP, Krance RA, Popat U, Carrum G, Margolin JF, Brenner MK. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood 107(4)(4):1332-1341, 2/15/2006. e-Pub 10/25/2005. PMCID: PMC16249392. | |
| 21. | Lamba R, Carrum G, Myers GD, Bollard CM, Krance RA, Heslop HE, Brenner MK, Popat U. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant 36(9)(9):797-802, 11/2005. PMCID: PMC16151431. | |
| 22. | Popat U, Frost A, Liu E, May R, Bag R, Reddy V, Prchal JT. New onset of myelofibrosis in association with pulmonary arterial hypertension. Ann Intern Med 143(6)(6):466-467, 9/20/2005. PMCID: PMC16172450. | |
| 23. | Burt RK, Cohen B, Rose J, Petersen F, Oyama Y, Stefoski D, Katsamakis G, Carrier E, Kozak T, Muraro PA, Martin R, Hintzen R, Slavin S, Karussis D, Haggiag S, Voltarelli JC, Ellison GW, Jovanovic B, Popat U, McGuirk J, Statkute L, Verda L, Haas J, Arnold R. Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol 62(6)(6):860-4, 6/2005. PMCID: PMC15956156. | |
Invited Articles | ||
| 1. | Popat U, Carrum G, Heslop HE. Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. Cancer Treat Rev 29(1):3-10, 2/2003. PMCID: PMC12633575. | |
Book Chapters | ||
| 1. | Popat U, Giralt S. Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia. In: Contemporary Hematology, Stem Cell Transplantation for Hematoligic and other Disorders. Ed(s) R.J. Soiffer. Humana Press: Totowa, NJ, 2008. | |
| 2. | Popat U, Giralt S. Hematopoietic cell transplantation for chronic myeloid leukemia and myelofibrosis. In: Chronic Myeloproliferative Disorders. Informa Press, 2008. | |
| 3. | Rice L, Popat U. Non-Hodgkin's Lymphoma. In: Conn's Current Therapy 2008. Ed(s) HF Conn, D Martin, L Gunzel. Saunders-Elsevier: United Kingdom, 458-461, 2008. ISBN: 978-1-4160-4435-2. | |
| 4. | Fanale M, Dabaja B, Anderlini P, Popat U. 60 Years of Survival Outcomes at The University of Texas M.D. Anderson Cancer Center. In: The MD Anderson Manual of Medical Oncology. Ed(s) Burke T, Rodriguez A, Walters R. Springer Science. Submitted. | |
Grant & Contract Support
| Title: | Phase I Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 17) to Enhance Engraftment in Adults Undergoing Double Cord Blood Transplantation |
| Funding Source: | US Biotest, Inc. |
| Role: | Principal Investigator |
| Duration: | 3/3/2010 - 3/2/2015 |
| Title: | Allogeneic stem cell transplantation for myelofibrosis using reduced intensity busulfan and fludarabine conditioning. |
| Funding Source: | Otsuka Pharmaceutical Company Ltd. |
| Role: | Principal Investigator |
| Duration: | 7/31/2009 - 7/31/2013 |
| Title: | Eltrombopag for post transplant thrombocytopenia |
| Funding Source: | GlaxoSmithKline |
| Role: | Principal Investigator |
| Duration: | 4/1/2009 - 3/31/2014 |
| Title: | High dose immunosuppression and autologous transplantation for multiple sclerosis (HALT MS) study |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| Duration: | 10/1/2006 - 2/28/2013 |
Last updated: 2/21/2013
- Global Navigation
- About Us
- Locations
- Calendar
- Careers
- Publications
- How You Can Help
- Contact Us
- Newsroom
- Site Index
- Patient and Cancer Information
- myMDAnderson
- Cancer Information
- Patient Information
- Care Centers & Clinics
- Children's Cancer Hospital
- Services & Amenities
- Education and Research
- Departments, Programs and Labs
- PeopleFinder
- Research at MD Anderson
- Education & Training
- Resources for Professionals
- For Employees
- Employee Alert Information
- Employee Resources
- Doing Business
- Vendors & Suppliers
- Partners & Affiliates
- Legal and Policy
- Legal Statements
- Site Policies
- Reporting Fraud, Waste & Abuse

